Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Over a 15 year period, half of patients with relapsing remitting multiple sclerosis (RR-MS) will develop secondary progressive-multiple sclerosis (SP-MS). Recombinant beta interferons (IFN-β) are well established for relapsing remitting-multiple sclerosis (RR-MS) but often they continue to be used as the first line treatment in the secondary progressive phase of the disease (SP- MS), without good evidence that they reverse or retard the progression of the disease.
There are several reasons why IFN-beta (IFN-β) are used in SP-MS: perception of clinical efficacy of IFN-β in SP-MS, difficulty informing the patient about the worsening of the condition in the progressive phase of the disease, the ‘force of habit’ of the clinician and the patient, and the current absence of therapeutic agents able to significantly change …
Competing interests None.
Provenance and peer review Commissioned; externally peer reviewed.